Summarized by Masters of Longevity from PR Newswire.
Update on a clinical-stage neurodegenerative biotech’s Nasdaq listing status and planned appeal while clinical programs advance.
Key Takeaways
- Nasdaq determined the company remains noncompliant with the $35 million minimum market value requirement.
- The company will request a Nasdaq Hearings Panel hearing seeking up to a 180-day exception to regain compliance.
- Nasdaq confirmed the company regained compliance with the $1.00 minimum bid price after a 1-for-20 reverse split.
